DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H2 2016" report to their offering.
'Polycystic Ovarian Syndrome - Pipeline Review, H2 2016'; Polycystic Ovarian Syndrome pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities Institutes.
Furthermore, the publisher says; Polycystic Ovarian Syndrome Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.
The report 'Polycystic Ovarian Syndrome - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Key Topics Covered:
- Introduction
- Polycystic Ovarian Syndrome Overview
- Therapeutics Development
- Pipeline Products for Polycystic Ovarian Syndrome - Overview
- Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis
- Polycystic Ovarian Syndrome - Therapeutics under Development by Companies
- Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes
- Polycystic Ovarian Syndrome Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Polycystic Ovarian Syndrome - Products under Development by Companies
- Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes
- Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Crinetics Pharmaceuticals, Inc.
- EffRx Pharmaceuticals S.A.
- Euroscreen S.A.
- Merck KGaA
- Millendo Therapeutics, Inc.
- Vicore Pharma AB
For more information about this report visit http://www.researchandmarkets.com/research/hkpjk2/polycystic
